keyword
MENU ▼
Read by QxMD icon Read
search

Drug eluting beads

keyword
https://www.readbyqxmd.com/read/28228906/histological-assessment-of-the-efficacy-of-drug-eluting-beads-in-portal-tumor-thrombosis-of-hepatocellular-carcinoma
#1
Yusuke Imai, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Eiji Takeshita, Masanori Abe, Hiroaki Tanaka, Mie Kurata, Sohei Kitazawa, Yoichi Hiasa
A 58-year-old man was diagnosed with advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT). The tumors were multiple and existed in both lobes. Drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) was performed for the tumors in the left lobe. Embosphere and Hepasphere were selected for embolization of the arterioportal shunt, followed by loaded epirubicin infusion into the left hepatic artery. Computed tomography showed reduction of PVTT. However, liver failure progressed, and the patient died 67 days after DEB-TACE...
March 2017: Radiology case reports
https://www.readbyqxmd.com/read/28193540/unusual-behaviour-induced-by-phase-separation-in-hydrogel-microspheres
#2
Clare L Heaysman, Gary J Philips, Andrew W Lloyd, Andrew L Lewis
: Hydrogel microspheres with the capability to interact with charged species such as various drugs by ion-exchange processes are useful in a variety of biomedical applications. Such systems have been developed to allow active loading of the microsphere with chemotherapeutic agents in the hospital pharmacy for subsequent locoregional therapy of tumours in the liver by drug-eluting bead chemoembolization (DEB-TACE). A variety of microspherical embolisation systems have been described, all based upon hydrogels bearing anionic functionalities to allow interaction with cationically charged drugs...
February 13, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28188808/characterization-of-a-novel-intrinsically-radiopaque-drug-eluting-bead-for-image-guided-therapy-dc-bead-lumi%C3%A2
#3
Koorosh Ashrafi, Yiqing Tang, Hugh Britton, Orianne Domenge, Delphine Blino, Andrew J Bushby, Kseniya Shuturminska, Mark den Hartog, Alessandro Radaelli, Ayele H Negussie, Andrew S Mikhail, David L Woods, Venkatesh Krishnasamy, Elliot B Levy, Bradford J Wood, Sean L Willis, Matthew R Dreher, Andrew L Lewis
We have developed a straightforward and efficient method of introducing radiopacity into Polyvinyl alcohol (PVA)-2-Acrylamido-2-methylpropane sulfonic acid (AMPS) hydrogel beads (DC Bead™) that are currently used in the clinic to treat liver malignancies. Coupling of 2,3,5-triiodobenzaldehyde to the PVA backbone of pre-formed beads yields a uniformly distributed level of iodine attached throughout the bead structure (~150mg/mL) which is sufficient to be imaged under standard fluoroscopy and computed tomography (CT) imaging modalities used in treatment procedures (DC Bead LUMI™)...
February 8, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28167071/on-column-trypsinization-allows-for-re-use-of-matrix-in-modified-multiplexed-inhibitor-beads-assay
#4
Voin Petrovic, Camilla Olaisen, Animesh Sharma, Anala Nepal, Steffen Bugge, Eirik Sundby, Bård Helge Hoff, Geir Slupphaug, Marit Otterlei
The Multiplexed Inhibitor Bead (MIB) assay is a previously published quantitative proteomic MS-based approach to study cellular kinomes. A rather extensive procedure, need for multiple custom-made kinase inhibitors and an inability to re-use the MIB-columns, has limited its applicability. Here we present a modified MIB assay in which elution of bound proteins is facilitated by on-column trypsinization. We tested the modified MIB assay by analyzing extract from three human cancer cell lines treated with the cytotoxic drugs cisplatin or docetaxel...
February 3, 2017: Analytical Biochemistry
https://www.readbyqxmd.com/read/28160267/third-line-treatment-of-colorectal-liver-metastases-using-debiri-chemoembolization
#5
Germano Scevola, Giorgio Loreni, Marco Rastelli, Stefano Sposato, Sara Ramponi, Vittorio Miele
To evaluate safety, efficacy of drug-eluting beads with irinotecan (DEBIRI) on local response and survival of patients affected by colorectal liver metastases (CRLM) progressing during or after second line was evaluated. Sixty-two patients, with colorectal liver metastases, not suitable for surgery or thermal ablation treatments, progressing during or within 6 month from the end of second-line chemotherapy, were treated with DEBIRI chemoembolization between February 2009 and July 2014. CRLM were histologically confirmed...
March 2017: Medical Oncology
https://www.readbyqxmd.com/read/28132823/preparation-and-characterisation-of-vandetanib-eluting-radiopaque-beads-for-locoregional-treatment-of-hepatic-malignancies
#6
Alice Hagan, Gary J Phillips, Wendy M Macfarlane, Andrew W Lloyd, Peter Czuczman, Andrew L Lewis
Since their introduction around a decade ago, embolic drug-eluting beads (DEBs) have become a well-established treatment option for the locoregional transarterial treatment of hepatic malignancies. Despite this success, the therapy is seen to be limited by the choice of drug and more effective options are therefore being sought. These include the small molecule multi-tyrosine kinase inhibitors (MTKi), which exert an anti-angiogenic and anti-proliferative effect that could be highly beneficial in combating some of the unwanted downstream consequences of embolization...
January 27, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28097503/blended-chitosan-paste-for-infection-prevention-preliminary-and-preclinical-evaluations
#7
Joel M Berretta, Jessica A Jennings, Harry S Courtney, Karen E Beenken, Mark S Smeltzer, Warren O Haggard
BACKGROUND: Local drug delivery devices offer a promising method for delivering vancomycin and amikacin for musculoskeletal wounds. However, current local delivery devices such as beads and sponges do not necessarily allow for full coverage of a wound surface with eluted antibiotics and do not address the need for reducing the antibiotic diffusion distance to help prevent contamination by bacteria or other microorganisms. We blended chitosan/polyethylene glycol (PEG) pastes/sponges to increase biocompatibility and improve antibiotic coverage within the wound...
January 17, 2017: Clinical Orthopaedics and related Research
https://www.readbyqxmd.com/read/28097502/should-we-routinely-use-debtace-for-unresectable-hcc-ctace-versus-debtace-a-single-center-survival-analysis
#8
M Massani, T Stecca, C Ruffolo, N Bassi
Conventional trans-arterial chemoembolization (cTACE) for intermediate stage hepatocellular carcinoma (HCC) achieves a partial response in up to 72% of patients and improves median survival. Drug-eluting-beads-TACE (DEBTACE) improves treatment efficacy and tolerance as compared to cTACE. Our aim was to retrospectively evaluate our experience in the treatment of intermediate/advanced HCC with cTACE versus DEBTACE. Overall survival (OS) was the first endpoint. We retrospectively considered our department register data between 2006 and 2012...
January 17, 2017: Updates in Surgery
https://www.readbyqxmd.com/read/28097096/impact-of-different-embolic-agents-for-transarterial-chemoembolization-tace-procedures-on-systemic-vascular-endothelial-growth-factor-vegf-levels
#9
Andreas Schicho, Claus Hellerbrand, Kristina Krüger, Lukas P Beyer, Walter Wohlgemuth, Christoph Niessen, Ernst Hohenstein, Christian Stroszczynski, Philippe L Pereira, Philipp Wiggermann
Background and Aims: Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoembolization (TACE). However, there appear to be side effects, such as induction of proangiogenic factors, e.g. vascular endothelial growth factor (VEGF), which have been shown to be associated with a poor prognosis. This prospective study was designed to compare serum VEGF level response after TACE with different embolic agents in patients with HCC. Methods: Patients were assigned to one of three different TACE regimens: degradable starch microspheres (DSM) TACE, drug-eluting bead (DEBDOX) TACE or Lipiodol TACE (cTACE)...
December 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28042235/novel-implications-in-the-treatment-of-hepatocellular-carcinoma
#10
REVIEW
Jan Best, Clemens Schotten, Jens M Theysohn, Axel Wetter, Stefan Müller, Sonia Radünz, Maren Schulze, Ali Canbay, Alexander Dechêne, Guido Gerken
Worldwide hepatocellular carcinoma remains one of the leading causes of cancer-related death, associated with a poor prognosis due to late diagnosis in the majority of cases. Physicians at care are frequently confronted with patients who are ineligible for curative treatment such as liver resection, transplantation or radiofrequency ablation. Besides established palliative locoregional therapies, such as ablation or chemoembolization, new treatment options, such as microwave ablation, drug-eluting bead transarterial chemoembolization or selective internal radiation therapy, are emerging; however, data from randomized controlled trials are still lacking...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28008454/intra-arterial-contrast-enhanced-ultrasound-ia-ceus-for-localization-of-hepatocellular-carcinoma-hcc-supply-during-transarterial-chemoembolization-tace-a-case-series
#11
Ilya Lekht, Megha Nayyar, Brian Luu, Phillip L Guichet, Jessica Ho, Ramon Ter-Oganesyan, Michael Katz, Mittul Gulati
Transarterial chemoembolization (TACE) is a proven catheter-based locoregional therapy for treatment of hepatocellular carcinoma (HCC). Drug-eluting bead TACE involves delivering micrometer-sized particles preloaded with doxorubicin directly to the tumor via its arterial blood supply and results in vascular embolization with intra-tumoral drug release. Effective therapy requires mapping of the tumor arterial supply, which in some cases cannot be accomplished with conventional angiographic techniques alone. Contrast-enhanced ultrasound (CEUS) is an imaging technique which utilizes microbubble contrast agents to demonstrate blood flow and tissue perfusion, enabling tumor visualization in real time...
December 23, 2016: Abdominal Radiology
https://www.readbyqxmd.com/read/28004168/review-of-the-clinical-evidence-for-the-use-of-debiri-in-the-treatment-of-colorectal-metastatic-disease
#12
Shamar Young, Donna D'Souza, Siobhan Flanagan, Jafar Golzarian
Colorectal cancer is a common malignancy that most commonly metastasizes to the liver. There has been considerable effort in developing new treatment options for these patients. One method that has been developed for the treatment of colorectal metastases to the liver is irinotecan-loaded drug-eluting bead (DEBIRI) embolization. This article reviews the current literature on DEBIRI and discusses the state of current knowledge and possible areas of future investigation.
December 21, 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28003766/a-pilot-study-employing-hepatic-intra-arterial-irinotecan-injection-of-drug-eluting-beads-as-salvage-therapy-in-liver-metastatic-colorectal-cancer-patients-without-extrahepatic-involvement-the-first-southern-italy-experience
#13
Girolamo Ranieri, Artor Niccoli Asabella, Corinna Altini, Vito Fazio, Luciana Caporusso, Ilaria Marech, Gianluca Vinciarelli, Francesco Macina, Dario de Ceglia, Margherita Fanelli, Michele Ammendola, Giuseppe Rubini, Cosmo Damiano Gadaleta
BACKGROUND: The main aim of this prospective study was to evaluate the efficacy of drug-eluting beads with irinotecan (DEBIRI) for liver metastases from colorectal cancer. Secondary aims were to evaluate survival and toxicity. METHODS: Twenty-five patients with metastases in <50% of the liver and without extrahepatic involvement were enrolled. Treatment response assessment was performed by multidetector contrast enhancement computed tomography (MDCT) with evaluation of the enhancement pattern of the target lesion and tumor response rates according to modified Response Evaluation Criteria in Solid Tumors (mRECIST, Version 1...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28000631/evaluation-of-the-viability-of-hepatocellular-carcinoma-in-the-caudate-lobe-using-contrast-enhanced-endoscopic-ultrasonography-after-transarterial-chemoembolization
#14
So Nakaji, Nobuto Hirata
A 71-year-old female was diagnosed with hepatocellular carcinoma (HCC). The tumor measured 65 mm in diameter and was located in the caudate lobe. Transarterial chemoembolization (TACE) was performed repeatedly; however, a follow-up dynamic computed tomography (CT) scan showed that the tumor remained viable. Thus, TACE was performed using drug-eluting beads that had been preloaded with epirubicin. Contrast-enhanced endoscopic ultrasonography (CE-EUS) was conducted for evaluating the treatment effects. First, we detected the internal part of the tumor...
November 2016: Endoscopic Ultrasound
https://www.readbyqxmd.com/read/27997198/in-vivo-drug-delivery-performance-of-lipiodol-based-emulsion-or-drug-eluting-beads-in-patients-with-hepatocellular-carcinoma
#15
Elsa Lilienberg, Ilse R Dubbelboer, Amar Karalli, Rimma Axelsson, Torkel B Brismar, Charlotte Ebeling Barbier, Agneta Norén, Frans Duraj, Mikael Hedeland, Ulf Bondesson, Erik Sjögren, Per Stål, Rickard Nyman, Hans Lennernäs
Doxorubicin (DOX) delivered in a lipiodol-based emulsion (LIPDOX) or in drug-eluting beads (DEBDOX) is used as palliative treatment in patients with intermediate-stage hepatocellular carcinoma (HCC). The primary objective of this study was to evaluate the in vivo delivery performance of DOX from LIPDOX or DEBDOX in HCC patients using the local and systemic pharmacokinetics of DOX and its main metabolite doxorubicinol (DOXol). Urinary excretion of DOX and DOXol and their short-term safety and antitumor effects were also evaluated...
January 5, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/27993355/intra-arterial-therapies-for-colorectal-cancer-liver-metastases-radioembolization-excluded
#16
REVIEW
Thierry de Baere, Lambros Tselikas, Valérie Boige, Michel Ducreux, David Malka, Diane Goéré, Eléonore Benahim, Frédéric Deschamps
During the past 20 years, advances in systemic therapies have improved overall survival of patients with Colorectal cancer Liver metastases (CRLM) from 6 to 24 months. By reaching CRLM via their preferential arterial vascularization, hepatic arterial infusion of chemotherapy (HAIC) has demonstrated improvement in response rate and deepness of response. Improvement in deepness of response is potentially helpful to convert no surgical patient to surgery. Recent HAIC regimens, including HAIC-FUDR plus systemic oxaliplatin/irinotecan, or HAIC-oxaliplatin plus systemic 5FU and cetuximab yielded a 92% and 90% response rate respectively, and conversion to R0 surgery in 47% and 42% of patients, respectively...
December 16, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27856136/korean-multicenter-registry-of-transcatheter-arterial-chemoembolization-with-drug-eluting-embolic-agents-for-nodular-hepatocellular-carcinomas-six-month-outcome-analysis
#17
Myungsu Lee, Jin Wook Chung, Kwang-Hun Lee, Jong Yun Won, Ho Jong Chun, Han Chu Lee, Jin Hyoung Kim, In Joon Lee, Saebeom Hur, Hyo-Cheol Kim, Yoon Jun Kim, Gyoung Min Kim, Seung-Moon Joo, Jung Suk Oh
PURPOSE: To assess the efficacy and safety of transcatheter arterial chemoembolization with drug-eluting embolic (DEE) agents for nodular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The study design was a prospective multicenter registry-based, single-arm clinical trial that included 152 patients. One hundred three (67.8%) had a Child-Pugh class/score of A5, 114 (75.0%) had a performance status of 0, and 77 (50.7%) had Barcelona Clinic Liver Cancer (BCLC) stage A disease...
November 14, 2016: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/27834009/predicting-outcomes-after-chemo-embolization-in-patients-with-advanced-stage-hepatocellular-carcinoma-an-evaluation-of-different-radiologic-response-criteria
#18
Andrew J Gunn, Rahul A Sheth, Brandon Luber, Minh-Huy Huynh, Niranjan R Rachamreddy, Sanjeeva P Kalva
PURPOSE: The purpse of this study was to evaluate the ability of various radiologic response criteria to predict patient outcomes after trans-arterial chemo-embolization with drug-eluting beads (DEB-TACE) in patients with advanced-stage (BCLC C) hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Hospital records from 2005 to 2011 were retrospectively reviewed. Non-infiltrative lesions were measured at baseline and on follow-up scans after DEB-TACE according to various common radiologic response criteria, including guidelines of the World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), the European Association for the Study of the Liver (EASL), and modified RECIST (mRECIST)...
January 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27833376/transarterial-chemoembolization-with-drug-eluting-beads-in-hepatocellular-carcinoma
#19
EDITORIAL
Hee Chul Nam, Bohyun Jang, Myeong Jun Song
Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia (conventional TACE). Recently, drug-eluting beads (DC Beads(®)) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor...
October 28, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27824665/tumor-enhancement-and-heterogeneity-are-associated-with-treatment-response-to-drug-eluting-bead-chemoembolization-for-hepatocellular-carcinoma
#20
Stephen P Reis, Patrick D Sutphin, Amit G Singal, Richard Grzybowski, Stephen Fisher, Christopher Ball, Yin Xi, Simer Grewal, Sanjeeva P Kalva
PURPOSE: Treatment response to drug-eluting bead chemoembolization (DEB-TACE) is well established for patients with hepatocellular carcinoma (HCC); however, few studies have evaluated tumor imaging characteristics associated with treatment responses. The aim of our study was to identify imaging characteristics associated with treatment responses and overall survival after DEB-TACE of HCC. METHODS: This is a retrospective cohort study of 33 tumors in 32 patients who underwent DEB-TACE for inoperable HCC in a single, large academic medical center...
November 7, 2016: Journal of Computer Assisted Tomography
keyword
keyword
8544
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"